Glaxo Loses Patent For Seretide/Advair In U.K.

Law360, New York (March 19, 2004, 12:00 AM EST) -- GlaxoSmithKline has lost a U.K. patent challenge from generic drug makers Cipla and Ivax on its top-selling athma drug Seretide (Advair).

Justice Pumfrey with the High Court ruled Friday that the patent for Seretide was “entirely obvious” and invalidated it.

Glaxo said it was considering whether to appeal the decision.

The case rested on whether Glaxo’s scientists took a truly inventive step in combining two older drugs, Flovent and Serevent, to make Seretide.

Cipla and Ivax had argued that the patent for the inhaled asthma treatment,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.